Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Ovarian cancer remains a leading cause of cancer-related deaths in women.
• Developing effective molecular-targeted therapies requires identifying key genes in carcinogenesis.
• Understanding the genetic basis of ovarian cancer is crucial for therapeutic advancements.

Purpose of the Study:

• To screen for genes involved in ovarian carcinogenesis.
• To identify potential molecular targets for ovarian cancer therapy.
• To investigate the role of specific genetic alterations in cancer development.

Main Methods:

• Construction of retroviral expression libraries from human ovarian cancer cell lines (SHIN-3 and TYK-CPr).
• Performance of focus formation assays using 3T3 cells to identify transforming genes.
• Genetic analysis of identified genes, including sequencing and mutation identification.
• Functional validation of identified mutations through gene expression in fibroblasts.

Main Results:

• Identification of proteasome subunit beta-type 2 (PSMB2), ubiquitin-specific protease 14 (USP14), and keratin 8 (KRT8) from SHIN-3 cells.
• Identification of polymerase II RNA subunit (POLR2E), chaperonin containing T-complex polypeptide 1 subunit 4 (CCT4), glia maturation factor beta (GMFB), and neuroblastoma ras viral oncogene homolog (NRAS) from TYK-CPr cells.
• A specific mutation (CAA → AAA substitution at codon 61) was found in the NRAS gene, leading to an amino acid change (Glu → Lys at position 61).
• Expression of the mutant NRAS in fibroblasts resulted in the formation of transformed foci, confirming its oncogenic potential.

Conclusions:

• Several genes, including NRAS, PSMB2, USP14, KRT8, POLR2E, CCT4, and GMFB, are implicated in ovarian carcinogenesis.
• The identified NRAS mutation exhibits transforming ability, highlighting its potential as a therapeutic target.
• These findings contribute to the development of novel molecular-targeted therapies for ovarian cancer.